ECOR electroCore

electroCore, Inc. to Present at Little Grapevine’s G1 Microcap Virtual Conference

electroCore, Inc. to Present at Little Grapevine’s G1 Microcap Virtual Conference

BASKING RIDGE, N.J., May 29, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that that a prerecorded virtual presentation featuring Dan Goldberger, Chief Executive Officer, will be available at Little Grapevine™ () beginning today, May 29, 2020, at 10:30 a.m. Eastern Standard Time.

Accompanying the presentation will be a short executive introduction, as well as a brief Q&A with Mr. Goldberger. A copy of the slides will be available at  and under the Investor Relations section of electroCore’s website: .

No fee is required to join or view the company’s Little Grapevine Conference presentation, as it is open to the public.

Register at to be notified when the event is about to begin.

About Little Grapevine

Little Grapevine is a web-based platform that invites companies to participate in on-line virtual conferences with video presentations, video interviews, podcasts and more. Content is available for free for the public and conveniently archived and categorized on littlegrapevine.com, which serves as an all-in-one tool for investors seeking to research companies in the microcap space. At the end of each presentation, featured companies also answer Little Grapevine’s questions about their business. For more information about Little Grapevine, please visit .

About electroCore, Inc.

electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology. The company’s initial targets are the preventative treatment of cluster headache and migraine and acute treatment of migraine and episodic cluster headache.

For more information, visit .

Investors:

Hans Vitzthum

LifeSci Advisors

617-430-7578

or

Media Contact:

Jackie Dorsky

electroCore

973-290-0097

EN
29/05/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on electroCore

 PRESS RELEASE

Acacia Clinics and Vagus Nerve Society Conduct Study Using electroCore...

Acacia Clinics and Vagus Nerve Society Conduct Study Using electroCore’s gammaCore Sapphire for Adjunctive Treatment of Symptoms Associated with Post-Traumatic Stress Disorder (“PTSD”) ROCKAWAY, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today announced that Acacia Clinics and the Vagus Nerve Society have launched a new research initiative to explore the extent to which gammaCore™ Sapphire, electroCore’s non-invasive vagus nerve stimulator (nVNS), can be used as an adjunctive treatment of s...

 PRESS RELEASE

electroCore Provides Preliminary Full-Year 2025 Business Update; Expec...

electroCore Provides Preliminary Full-Year 2025 Business Update; Expects ~26% Revenue Growth to ~$31.8–$32.0 Million Record revenue of approximately $31.8 - $32.0 million for full-year 2025 and approximately $9.0 - $9.2 million for the three months ended December 31, 2025 Revenue growth of approximately 26% over full-year 2024Cash, cash equivalents, and marketable securities (“Total Cash”) balance of approximately $11.6 million as of December 31, 2025 ROCKAWAY, N.J., Jan. 20, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic tech...

 PRESS RELEASE

TAC-STIM Demonstrates Significant Performance Improvements in Active-D...

TAC-STIM Demonstrates Significant Performance Improvements in Active-Duty United States Air Force Airmen ROCKAWAY, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today announced the publication of a peer reviewed paper titled “Non-Invasive Transcutaneous Vagal Nerve Stimulation Enhances Mood, Task Performance, and Learning in a High-Stress Military Training Environment” which will be presented at the Applied Human Factors and Ergonomics (AHFE2025) Conference on December 8, 2025. The paper pres...

 PRESS RELEASE

electroCore to Participate at the Canaccord Genuity MedTech, Diagnosti...

electroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum ROCKAWAY, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum. The conference will take place in New York on Thursday, November 20, 2025 at The Westin NY Grand Central Hotel. Management will host one-on-one meetings throughout the day. Investors who wish to request a...

 PRESS RELEASE

electroCore Announces Third Quarter 2025 Financial Results

electroCore Announces Third Quarter 2025 Financial Results Net sales of $8.7 million increased 33% vs. Q3 2024; YTD net sales of $22.8 million increased 26% vs. first nine months of 2024 Cash, cash equivalents, restricted cash, and marketable securities (“Total Cash”) of $13.2 million as of September 30, 2025  Company to host a conference call and webcast today, November 5, 2025, at 4:30 p.m. EDT ROCKAWAY, N.J., Nov. 05, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today announced financial results for t...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch